Does Rallies show 13F holders for INKT?

Yes. Rallies tracks hedge fund and 13F ownership data for INKT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INKT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INKT. It does not provide personalized investment advice.

INKT (MiNK Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

MiNK Therapeutics, Inc. Common Stock (INKT) is a publicly traded Healthcare sector company. As of May 21, 2026, INKT trades at $10.29 with a market cap of $50.02M and a P/E ratio of -3.67. INKT moved +4.15% today. Year to date, INKT is -11.11%; over the trailing twelve months it is +48.60%. Its 52-week range spans $4.56 to $76.00. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces INKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INKT stock?

Hedge funds tracked by Rallies that own INKT include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MiNK Therapeutics, Inc. Common Stock.

INKT Key Metrics

Key financial metrics for INKT
Metric	Value
Price	$10.29
Market Cap	$50.02M
P/E Ratio	-3.67
EPS	$-2.93
Dividend Yield	0.00%
52-Week High	$76.00
52-Week Low	$4.56
Volume	32
Avg Volume	0
Revenue (TTM)	$180.25K
Net Income	$-12.49M
Gross Margin	0.00%

Top Hedge Funds Holding INKT

Renaissance Technologies holds 101.71K shares of INKT, changed -4.67% as of Dec 31, 2024.
Citadel Advisors holds 19.73K shares of INKT, changed -51.96% as of Mar 31, 2024.

Latest INKT News

MiNK Therapeutics Opens 90-Patient Phase II ARDS Trial with H2 2026 Readouts — May 16, 2026
MiNK Therapeutics’ AgenT-797 Combo Shows 77% Control, 6.9-Month PFS and 9.5-Month OS — Apr 17, 2026
MiNK Therapeutics to Showcase AgenT-797 Immune Modulation in Cancer and ARDS at ASGCT — Apr 2, 2026
MiNK Therapeutics Boosts Cash to $13.4M, Cuts Costs 40%, Advances Phase 2 Trials — Mar 31, 2026
MiNK Therapeutics Secures $16.4M Runway, Starts ARDS Phase 2 in 1H 2026 — Mar 31, 2026

Recent INKT Insider Trades

Ryan Barbara sold 300 (~$4.58K) on Mar 10, 2026.
Ryan Barbara sold 500 (~$7.78K) on Mar 10, 2026.
Ryan Barbara sold 500 (~$7.65K) on Mar 10, 2026.

INKT Analyst Consensus

1 analysts cover INKT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.

Common questions about INKT

Who owns INKT stock?: Hedge funds tracked by Rallies that own INKT include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MiNK Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for INKT?: Yes. Rallies tracks hedge fund and 13F ownership data for INKT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INKT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INKT. It does not provide personalized investment advice.